Preimplantation genetic testing for aneuploidies (PGT-A, previously known as preimplantation genetic screening or PGS) provides information on the chromosomal content of cell samples from blastocysts with the intent of helping inform decisions about embryo transfer.

PGT-A was initially designed to classify IVF embryos as euploid (containing the correct amount of chromosomal material) or aneuploid (containing extra or missing chromosomal material) because of the known association between advanced maternal age and increased occurrence of aneuploidy.

However, recent advancements in PGT-A technology have expanded the range of possible results to include an intermediate between euploid and aneuploid: mosaic, raising new questions about PGT-A and the clinical impact of mosaicism.

Evidence for PGT-A

As first reported in Harton et al. 2013 and now also observed in the latest SART data, IVF with PGT-A can effectively reverse the maternal age effect on implantation rates, especially for frozen transfers.¹

In addition, since the advent of PGT-A, the available scientific evidence is overwhelming that euploid embryos have lower miscarriage rates and higher ongoing pregnancy rates per transfer than embryos replaced at random, at least for patients 35 and older.²⁻⁶

Because of the increased likelihood of success a tested euploid embryo has over an untested embryo, PGT-A has also enabled a shift from multiple embryo transfer to single embryo transfer, reducing patients’ risk of complications associated with twin and other multiple gestations.³

While the data on euploid embryo transfer is robust and conclusive, the research on mosaic embryos continues to evolve.
Mosaicism: What It Is and How It Happens

In the context of PGT-A, mosaicism is understood as an embryo containing two or more distinct cell lines; the example most relevant here is an embryo containing a mix of euploid and aneuploid cells. Although the concept of mosaicism has been recognized in biology for some time, it is only with the increased sensitivity of some next-generation sequencing (NGS) technology platforms that it has been reliably detected in preimplantation embryos.

While aneuploidy in an entire embryo typically arises as a result of meiotic errors during gamete formation, mosaicism arises through mitotic errors during embryo division. As mosaicism is a result of mitotic, not meiotic, errors, it has not been shown to be associated with maternal age.

The Clinical Relevance of Mosaicism

About 10-20% of PGT-A results using high resolution NGS techniques are mosaic. Previous methodologies only classified embryos as euploid or aneuploid, we have been unknowingly transferring mosaic embryos for years. Mosaic embryos have been shown to implant less and miscarry more than euploid embryos, but they can still sometimes lead to healthy live birth. Indeed, as an in-between result, mosaic embryos’ chance of producing a viable pregnancy is intermediate between that of a euploid embryo and an aneuploid embryo.

A recent internal study compared three key indicators of embryo viability—implantation, miscarriage, and ongoing pregnancy rates—between different groups of embryos; the results indicated viable potential for mosaic embryos, though significantly different from that of euploid embryos. Embryos with a low level of mosaicism (<40% abnormality detected) had an ongoing implantation rate (OIR) of 50%, compared to 30% for higher level mosaics, which was significant.

Overall, mosaic embryos had a 24% miscarriage rate, compared to 7% for euploid embryos (p<0.001), and an OIR of 37% per cycle of mosaic (20-80% abnormal) embryo transfer, compared to 77% after euploid embryo transfer (p<0.001).

Unlike aneuploidy, mosaicism is thought to be independent of maternal age. However, the number of embryos clinically classified as mosaic decreases slightly with age, as shown here. This is due to the increased likelihood that an embryo with a mosaic abnormality will also have a meiotic aneuploidy, which would result in that embryo being classified as ‘aneuploid’ rather than ‘mosaic’.
Society Guidelines

To date, only two societies have issued guideline statements regarding mosaic embryos and recommendations for clinical practice. The first guidelines were shared by the Preimplantation Genetic Diagnosis International Society (PGDIS) in July of 2016; when reporting PGT-A results, the guidelines suggested a ‘cut-off point’ at >20% abnormality detected. Lower levels (<20%) would thus be classified as normal (euploid), >80% abnormal (aneuploid), and the range between 20-80% mosaic.11

At this stage, outcomes data from the transfer of known mosaic embryos was very limited and further recommendations were made on the knowledge obtained from reproductive outcomes where fetal or placental mosaicism had been identified. These chromosome-based recommendations suggested de-prioritization of mosaicism involving chromosomes 2, 7, 13, 14, 15, 16, 18, and 21 based upon their impact on live birth and pregnancy outcomes.

When the Congress on Controversies in Preconception, Preimplantation, and Prenatal Genetic Diagnosis (COGEN) issued their statement soon after, knowledge had already evolved to add an additional comment on the impact the level of mosaicism (low degree versus high degree) can have on an embryo.12

More recently, a study published in Reproductive BioMedicine Online considered four parameters to determine a ‘scoring system’ for embryos based on chromosome change, including the risk for fetal involvement, uniparental disomy, miscarriage, and viable aneuploidy. The result was a comprehensive breakdown of which chromosomes and in what configuration (trisomic versus monosomic) to prioritize for transfer.13 While complicated at first glance, such ‘personalized’ recommendations are where the ultimate answer may lay as we learn more and more about outcomes of known mosaic embryo transfers.

PGDIS Guidelines

<table>
<thead>
<tr>
<th>EUPLOID</th>
<th>MOSAIC</th>
<th>ANEUPLOID</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;20% abnormality</td>
<td>20-80% abnormality</td>
<td>&gt;80% abnormality</td>
</tr>
</tbody>
</table>
Preimplantation genetic testing for aneuploidies (PGT-A, previously referred to as preimplantation genetic screening or PGS) is a genetic test designed to improve IVF success rates by providing information about the number of chromosomes in an embryo.

Embryos with the correct number of chromosomes (called euploid) have a higher chance of leading to a successful pregnancy than those with the incorrect number of chromosomes (called aneuploid). However, recent advances in PGT-A technology have uncovered a third class of PGT-A results that lie somewhere in between. This new class, deemed mosaic embryos, contain a mix of normal and abnormal cells.

Euploid embryos are obviously one’s best shot at success, yet data suggest that mosaics account for 10-20% of all PGT-A-tested embryos. That being the case, the most common question asked by patients when reviewing their PGT-A results is, “What would this mosaic result mean for a pregnancy or a baby?”

The answer is complicated. While mosaicism has always existed, it has only been reliably detectable for a couple of years, so research and follow-up studies are still ongoing. There are some preliminary professional medical society statement by the Preimplantation Genetic Diagnosis International Society (PGDIS) Position Statement recommended prioritizing mosaic embryos for transfer based on the level of mosaicism and the specific chromosome involved. Similarly, the Congress on Controversies in Preconception, Preimplantation, and Prenatal Genetic Diagnosis (CoGEN) updated a position statement on the matter following their annual meeting in Barcelona in 2017.

To find out more about mosaicism ask your sales representative for our clinician’s guide.

Find out more about mosaic embryos in our blog feed: fertility.coopersurgical.com/how-to-prioritize-mosaic-embryos-and-download-our-Clinician’s-Guide-to-Mosaicism

Subscribe to this newsletter and receive the latest news on innovative new techniques, processes and advancements in IVF at fertility.coopersurgical.com/ARTScientific

References


Santiago Munné PhD

Dr Munné studied genetics at the University of Pittsburgh and Cornell University Medical College, New York, where he developed the first PGT method to detect chromosome abnormalities. He became Director of PGT at The Institute for Reproductive Medicine and Science of Saint Barnabas in 1995, where he developed the first test to detect chromosome translocations.

In 2001, Dr Munné co-founded Reprogenetics and, alongside his colleagues, was rewarded numerous SART prize papers and the ASRM Star Award consecutively between 2011 and 2017 for his work and research. In 2011, he co-founded Recombine, which launched CarrierMap for screening gene defects. In 2016, he became the Chief Scientific Officer for CooperGenomicsSM following the acquisition of Reprogenetics, Recombine and Genesis Genetics by The Cooper Companies. In 2017, Dr Munné co-founded genomics company, Phosphorous, as well as MedAnswers – a infertility digital health platform, and Overture Life, a company focused on improving ART. He is an adjunct professor at Yale University and is the co-founder of the Preimplantation Genetic Diagnosis International Society (PGDIS).

Keep up with the latest at fertility.coopersurgical.com/news